UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/932,678	08/16/2001	Ronald H. Reeder	14538A005810	5058

20350 7590 04/09/2003

TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

EXAMINER	
YU, MISOOK	
ART UNIT	**PAPER NUMBER**
1642	

DATE MAILED: 04/09/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/932,678	REEDER ET AL.	
	Examiner	Art Unit	
	MISOOK YU, Ph.D.	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *16 January 2003* .

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-44* is/are pending in the application.

4a) Of the above claim(s) *6 and 25-38* is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-5,7-24 and 39-44* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .
4) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☒ Other: Seq. Alignment

DETAILED ACTION

This application contains claims 6, and 25-38 drawn to an invention nonelected with traverse in Paper No. 7. A complete reply to the final rejection must include cancelation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claims 1-44 are pending and Claims 6, and 25-38 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b).

Claims 1-5, 7-24, and 39-44 are examined on merits.

Claim Rejections - 35 USC § 112

Claims 1,2, 4, 7, 10-13, and 16-23 **remain rejected** and the new claims 39-44 are also rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had **possession** of the claimed invention.

Applicant argues that the necessary common attribute of the instantly claimed genus is the ability to hybridize to a poynucleotide encoding SEQ ID NO:2 under the recited condition; hybridization properties of nucleic acids are highly predictable in the art; because highly stringent conditions yield structurally similar DNAs, a person of ordinary skill in the art would not expect substantial variation among species encompassed within the scope of the claims. These arguments are not persuasive because the specification does not describe the identifying functional and structural characteristics of the hybridizing species encompassed by the scope of instantly claimed invention. The Office maintains hybridizing under the recited condition is not enough for satisfying written description requirement for structural characteristics of what is being claimed in relation to the limitation "a polynucleotide that codes for human RRN3 polypeptide" because the specification says that the human RRN3 cDNA is recently discovered by applicant and the terms human RRN3 is not well known in the art. The terms human RRN3 describing the gene or human Rrn3 recited in the claims

still read on an allelic variant or species homologs that the specification do not describe as stated in the previous Office action. Note the specification at pages 13 and 14. Further, the hybridizing species lack correlation between their structures to their function(s).

35 U.S.C. 112, First Paragraph, Scope Rejection

Claims 1,2, 4, 7, 10-13, and 16-23 **remain rejected** and the new claims 39-44 are also rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling DNA encoding a protein to stimulate ribosomal RNA transcription, does not reasonably provide enablement for how to **use any other hybridizing nucleic acid molecules that do not encode a protein capable of stimulating ribosomal RNA stimulation**. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Applicant argues that instant invention is drawn to nucleic acid molecules encoding a protein that could be used in stimulating ribosomal RNA transcription but this argument is not persuasive because the argument is not commensurate in the scope of claims. The claimed nucleic acid species encompass nucleic acid molecules that do not necessarily encode a protein capable of stimulating ribosomal RNA transcription.

Claim Rejections - 35 USC § 101

Rejection of claims under 35 U.S.C. 101 because the claimed invention is not supported by either a credible, specific and substantial asserted utility or a well established utility **is withdrawn** because applicant's argument that SEQ ID NO:1 encodes SEQ ID NO:2 capable of stimulating ribosomal RNA transcription is credible. Use of the instant invention in stimulating ribosomal RNA transcription is substantial and specific to the protein encoded by the claimed product.

Rejection of claims under 35 U.S.C. 112, first paragraph, specifically, since the claimed invention is not supported by either a either a credible, specific and substantial asserted utility or a well established utility is also withdrawn because as stated above

under utility rejection that applicant's argument the utility of the nucleic acid encoding the protein capable of stimulating ribosomal RNA transcription is substantial, credible, and specific.

NEW GROUNDS OF REJECTION

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

> The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1 and 7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. This rejection affects all the claims depending from claims 1 and 7 as well.

Claims 1 and 7 are confusing because it is not clear what constitutes the scope of Rrn3 polypeptide based on the last three lines of claim 1 and lines 7-9 of claim 7. The recited limitation "wherein the Rrn3 polypeptide, ...a fragment thereof" appears to say that Rrn3 polypeptide is defined as any RNA Pol 1 transcription factor because "a fragment thereof" could be a single amino acid, therefore any RNA Pol 1 transcription factor such as Rrn6 shown at Figure 2 of Keys et al (IDS, 1996,Genes and Development, vol. 8 pages 2349-2362) could belong to Rrn3 polypeptide of the instant claims.

Claim 39, 40, 43, and 44 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to **enable** one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims say that full complement of a nucleic acid molecule encoding a protein also encodes protein. The instant specification discloses the instantly claimed nucleic acid encodes a human protein. A complement of human DNA encoding a protein is called antisense DNA which does not usually encode a protein except in rare occasions and the specification does not teach the complement of a DNA encoding the protein also encode a protein.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 39 is rejected under 35 U.S.C. 102(b) as being anticipated by WO 99/0549 (11 February 1999, pages 1, 201, and 202 only).

Claim 39 is interpreted as drawn to any nucleic acid molecule capable of hybridizing to SEQ ID NO:1. Note the claim construction of (d). WO 99/0549 teaches nucleic acid molecule capable of hybridizing to instant SEQ ID NO:1. Note the sequence alignment.

Allowable Subject Matter

SEQ ID NO:1 is free of art. However, the Office would like to remind applicant that US Patent Application Publication No. US2002/0146801 A1 (Oct. 10, 2002) with earlier filing date than that of the instant application, claims nucleic acids encompassed by instant claims 1, 2, 4, 10-13, 16-23, 39-44. Note claims 1-3, 6, 7, and 9 of US2002/0146801 A1.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 703-308-2454. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony C Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

MARY E. MOSHER
PRIMARY EXAMINER
GROUP ~~1800~~ 1600

Misook Yu
April 3, 2003

RESULT 10
ABA83038
ID ABA83038 standard; DNA; 1461 BP.
XX
AC ABA83038;
XX
DT 05-FEB-2002 (first entry)
XX
DE Human transcription factor TRFX-65 coding sequence.
XX
KW Human; transcription factor; TRFX; cell proliferative disease;
KW autoimmune disease; inflammation; neurological disease;
KW developmental disorder; cancer; AIDS; infection; cytostatic; anti-HIV;
KW neuroprotective; antiinflammatory; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200172777-A2.
XX
PD 04-OCT-2001.
XX
PF 13-MAR-2001; 2001WO-US08117.
XX
PR 13-MAR-2000; 2000US-0188986.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Hillman JL, Baughn MR, Yue H, Lal P, Lu DAM, Patterson C;
PI Azimzai Y, Bandman O, Tang YT, Mathur P, Shah P, Au-Young J;
PI Reddy R;
XX
DR WPI; 2001-570896/64.
DR P-PSDB; ABB50214.
XX
PT Novel transcription factor polypeptides, used to treat diseases
PT associated with altered activity and expression of TRFX, and to screen
PT for agents capable of modulating its activity -
XX
PS Claim 11; Page 299; 327pp; English.
XX
CC The present sequence is the coding sequence for a human transcription
CC factor. The transcription factor and its coding sequence are useful in
CC the diagnosis, treatment and prevention of diseases associated with
CC altered expression of the transcription factor e.g. cell proliferative,
CC autoimmune/inflammatory, neurological and developmental disorders. A
CC number of specific disorders/diseases are given in the specification,
CC including: arteriosclerosis, cirrhosis, hepatitis, cancers, AIDS,
CC allergies, anaemia, asthma, autoimmune thyroiditis, bronchitis, atopic
CC dermatitis, diabetes mellitus, emphysema, Goodpasture's syndrome, gout,
CC Grave's disease, multiple sclerosis, osteoarthritis, pancreatitis,
CC psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative
CC colitis, uveitis, Alzheimer's disease, Huntington's disease, Parkinson's
CC disease, stroke, and viral, bacterial, fungal and protozoal infections.
XX
SQ Sequence 1461 BP; 413 A; 335 C; 298 G; 415 T; 0 other;

Query Match 20.3%; Score 420.8; DB 22; Length 1461;
Best Local Similarity 97.3%; Pred. No. 3.1e-113;
Matches 428; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

```
Qy   1188 ttcaaattgggattcgcagaggcatttttggaacatctctggaaaaaattgcaggaccca 1247
          || ||  ||||||||||||||||||||||||||||||||| |||||||| |||||||| |||
Db    530 tttaatatgggattcgcagaggcatttttggaacatctttggaaaaacttgcaggatcca 589

Qy   1248 agtaatcctgccatcatcaggcaggctgctggaaattatattggaagctttttggcaaga 1307
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    590 agtaatcctgccatcatcaggcaggctgctggaaattatattggaagctttttggcaaga 649

Qy   1308 gctaaatttattcctcttattactgtaaaatcatgcctagatcttttggttaactggctg 1367
          |||||||||||| |||||||||||||||||| ||||||||||||||||||||||||||||
Db    650 gctaaatttatttctcttattactgtaaaaccatgcctagatcttttggttaactggctg 709

Qy   1368 cacatataccttaataaccaggattcgggaacaaaggcattctgccatgttgctctccat 1427
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    710 cacatataccttaataaccaggattcgggaacaaaggcattctgccatgttgctctccat 769

Qy   1428 ggaccatttactcagcctgccaagctgtgttctacaccttttgttttagacacaaaaag 1487
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    770 ggaccatttactcagcctgccaagctgtgttctacaccttttgttttagacacaaaaag 829

Qy   1488 cttttgagcggaaacctgaaagaaggtttgcagtatcttcagagtctgaatttttaaaggg 1547
          |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db    830 cttttgagcggaaacctgaaagaaggtttgcagtatcctcagagtctgaatttttaaaggg 889

Qy   1548 atagtgatgagccagctaaatcccctgaagatttgcctgccctcagtgtttaaattttttt 1607
          |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||
Db    890 atagtgatgagccagctaaatcccctgaagatttgcctgccctcagtgtttaaattttttt 949

Qy   1608 gctgcaatcacaaataagta 1627
          |||||||||||||| | | |
Db    950 gctgcaatcacaaagatgaa 969
```

RESULT 11
AAX51663
ID AAX51663 standard; cDNA; 437 BP.
XX
AC AAX51663;
XX
DT 21-JUN-1999 (first entry)
XX
DE Human secreted protein 5' EST SEQ ID NO:242.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition; ds.
XX
OS Homo sapiens.
XX
PN WO9906549-A2.
XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB01231.
XX
PR 01-AUG-1997; 97US-0905279.
XX
PA (GEST) GENSET.
XX
PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX
DR WPI; 1999-153779/13.
DR P-PSDB; AAY12885.
XX
PT New nucleic acids encoding human secreted proteins - obtained from
PT cDNA libraries derived from testis, ovary, uterus and spleen tissue
XX
PS Claim 1; Page 344-345; 522pp; English.
XX
CC AAX51459 to AAX51691 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins, and encode the proteins given in AAY12867 to
CC AAY12913, respectively. The proteins given represent the signal peptide
CC and an N-terminal fragment of a secreted protein. The nucleic acid
CC sequences can be used for producing secreted human gene products. They
CC can also be used to develop products for diagnosis and therapy. The
CC proteins obtained may have cytokine activity, cell
CC proliferation/differentiation activity, haematopoiesis regulation
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/ chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.

```
CC   The sequences can also be used for obtaining corresponding promoter
CC   sequences. The nucleic acids encoding the signal peptide can be used for
CC   directing extracellular secretion of a polypeptide or the insertion of a
CC   polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ   Sequence 437 BP; 118 A; 85 C; 102 G; 131 T; 1 other;

  Query Match             20.3%;  Score 420;  DB 20;  Length 437;
  Best Local Similarity   98.4%;  Pred. No. 2.6e-113;
  Matches  423;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy        113 cgcttcgtcctctgcagttaagaagctgggcgcgtcgaggactgggatttcaaatatgcg 172
              |||||||||||||||||   |||| |||||||||||||||||||||||||||||||||||
Db          2 cgcttcgtcctctgcagtcaagacgctgggcgcgtcgaggactgggatttcaaatatgcg 61

Qy        173 tgcattagagaatgacttttttcaattctcccccaagaaaaactgttcggtttggtggaac 232
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db         62 tgcattagagaatgattttttcaattctcccccaagaaaaactgttcggtttggtggaac 121

Qy        233 tgtgacagaagtcttgctgaagtacaaaaagggtgaaacaaatgactttgagttgttgaa 292
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        122 tgtgacagaagtcttgctgaagtacaaaaagggtgaaacaaatgactttgagttgttgaa 181

Qy        293 gaaccagctgttagatccagacataaaggatgaccagatcatcaactggctgctagaatt 352
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        182 gaaccagctgttagatccagacataaaggatgaccagatcatcaactggctgctagaatt 241

Qy        353 ccgttcttctatcatgtacttgacaaaagactttgagcaacttatcagtattatattaag 412
              ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| ||
Db        242 ccgttcttctgtcatgtacttgacaaaagactttgagcaacttatcagtattatattgag 301

Qy        413 attgccttggttgaatagaagtcaaacagtagtggaagagtatttggcttttcttggtaa 472
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        302 attgccttggttgaatagaagtcaaacagtagtggaagagtatttggcttttcttggtaa 361

Qy        473 tcttgtatcagcacagactgttttcctcagaccgtgtctcagcatgattgcttcccattt 532
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        362 tcttgtatcagcagagactgttttcctcagaccgtgtctcagcatgattgcttcccattt 421

Qy        533 tgtgcctccc 542
              | ||||||||
Db        422 tgwgcctccc 431
```

```
RESULT 12
AAS91991
ID   AAS91991 standard; cDNA; 560 BP.
XX
AC   AAS91991;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #27795.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT, Liu C, Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   P-PSDB; ABG27804.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity -
XX
PS   Claim 1; SEQ ID No 27795; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS64197-AAS94564 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 560 BP; 178 A; 96 C; 109 G; 177 T; 0 other;

  Query Match             19.2%;  Score 398;  DB 23;  Length 560;
  Best Local Similarity   89.0%;  Pred. No. 9.4e-107;
  Matches  486;  Conservative    0;  Mismatches   55;  Indels [illegible];  Gaps [illegible];

Qy        202 ccccaagaaaaactgttcggtttggtggaactgtgacagaagtcttgctgaagtacaaaa [illegible]
Db          1 ccccaagaaaaactgttcagtttggtggaactgtgacagaagtcttgctgaaatacaaaa [illegible]

Qy        262 agggtgaaacaaatgactttgagttgttgaagaaccagctgttagatccagacataaag [illegible]
Db         61 cgggtgaaacaaatgactttgagttgttgaagaaccagctgttagatccagacataaaga [illegible]

Qy        322 atga-ccagatcatcaactggctgctagaattccgttcttctatcatgtacttga caaa [illegible]
Db        121 atgacccagatcatcaactggctgctagaattccgttcttctgtcatgtacttgacaaaa [illegible]

Qy        380 agactttgag-caacttatcagtattatattaagattgccttggttgaatagaag [illegible]
Db        181 agactttgagccaacttatcagtattatattgagattgccttggttgaatagaagtcaa [illegible]

Qy        438 acagtagtggaagagtatttggcttttcttggtaatcttgtatcagcacagactgt [illegible]
Db        241 acagtagtggaagagtatttggcttttcttggtaatcttgtatcagcatagactgt [illegible]

Qy        498 ctcagaccgtgtctcagcatgattgctt-cccatttgtgcctcccgagtgatcattaa [illegible]
Db        301 ctcagaccgtgtctcagcatgattgcttccccatttgtgcctcccgagtgatcattaa [illegible]

Qy        557 ggaaggcgatgtagatgtttcagattctgatgatgaagatgataatcttcctgcaaat [illegible]
Db        361 ggaaggcgatgtagatgtttcagattctgatgatgaagatgataatcttcctgcaaat [illegible]

Qy        617 tgacacatgtcacagagccttgcaaataatagcaagatatgtaccatcgacacgtgat [illegible]
Db        421 tgacacatatcacagagccttgcaaataatagcaagatatgtaccatcatgatat [illegible]

Qy        677 tctcatgccaatactggtggaaaaatttccatttgttcgaaaatcagagagaacactaa [illegible]
```